GR3005362T3 - - Google Patents

Info

Publication number
GR3005362T3
GR3005362T3 GR920401695T GR920401695T GR3005362T3 GR 3005362 T3 GR3005362 T3 GR 3005362T3 GR 920401695 T GR920401695 T GR 920401695T GR 920401695 T GR920401695 T GR 920401695T GR 3005362 T3 GR3005362 T3 GR 3005362T3
Authority
GR
Greece
Prior art keywords
interferon
viruses
delta
humans
administering
Prior art date
Application number
GR920401695T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3005362T3 publication Critical patent/GR3005362T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/811Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GR920401695T 1985-12-11 1992-08-06 GR3005362T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/807,887 US4806347A (en) 1985-12-11 1985-12-11 Interferon combinations

Publications (1)

Publication Number Publication Date
GR3005362T3 true GR3005362T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-24

Family

ID=25197366

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920401695T GR3005362T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-12-11 1992-08-06

Country Status (7)

Country Link
US (1) US4806347A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0225759B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS62145029A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE76579T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3685484D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2036526T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3005362T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2039276T3 (es) * 1987-01-20 1993-09-16 Schering Corporation Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
NZ534307A (en) 1999-09-17 2005-07-29 Wellstat Biologics Corp Use and detection of an oncolytic virus
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
EP1450848A4 (en) * 2001-10-05 2005-11-09 Intermune Inc METHODS OF TREATING HEPATIC FIBROSIS AND HEPATITIS C VIRUS INFECTION
WO2004078194A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
MXPA05009526A (es) 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
RS20060259A (en) 2003-10-14 2008-08-07 Intermune Inc., Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2006094385A1 (en) 2005-03-07 2006-09-14 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species

Also Published As

Publication number Publication date
ES2036526T3 (es) 1993-06-01
JPS62145029A (ja) 1987-06-29
EP0225759B1 (en) 1992-05-27
US4806347A (en) 1989-02-21
ATE76579T1 (de) 1992-06-15
DE3685484D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-07-02
EP0225759A2 (en) 1987-06-16
EP0225759A3 (en) 1989-02-08

Similar Documents

Publication Publication Date Title
EP0154344A3 (en) Antiviral pharmaceutical preparations and methods for their use
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
IL75717A0 (en) Tumor necrosis factor
IL75597A (en) Synergistic mixtures of interferons and tumour necrosis factor
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
IL76932A (en) Synergistic pharmaceutical analgesic compositions containing dihydrocodeine and ibuprofen
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
RO115700B1 (ro) Metodă de tratament cu interferon
DE3685484D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
NZ227944A (en) Synergistic pharmaceutical composition of a hybrid interferon and a muramylpeptide
IE893618L (en) Lactamimides in the treatment of drug-resistant protozoal¹infections
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
EP0285441A3 (en) Synergistic immunostimulating composition and method
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
GB2179858B (en) Compositions for treating viral skin diseases.
FI871545A7 (fi) Menetelmä syövän hoitoon käytettävän synergistisen seoksen valmistamiseksi, joka sisältää interleukiini-2:ta ja/tai interferoni- :aa ja kasvainnekroositekijää.
EP0273778A3 (en) Synergistic behavior of csf-1 and g-csf
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
MY110041A (en) Composition and method of treating hepatitis c
ES285527U (es) Estante perfeccionado
MY104115A (en) Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
MY104932A (en) Immunomodulatory azaspiranes